The massive costs of clinical trials have contributed to a situation where only a small proportion of potentially valuable ideas or treatments receive funding for translational research.

The massive costs of clinical trials have contributed to an acute situation where only a small proportion of potentially valuable ideas or treatments receive funding for translational research.

Explanation:

Worldwide investments in the creation of new medicines have already exceeded $100 billion per year, half of which is the cost of clinical trials. Currently, about 10,000 new molecules are at the stage of clinical study, of which about 500 each year reach the 3rd phase of clinical trials - a kind of “finish line” before becoming a drug for widespread medical use.